The Bottom Line
Female pattern hair loss (FPHL) affects about 40% of women by age 50. Unlike men, women typically notice diffuse thinning across the top of the scalp rather than a receding hairline. It's caused by a combination of genetics, hormones, and aging.
The first-line treatment is minoxidil (Rogaine) 5% foam or 2% solution applied to the scalp daily. For women with hormonal contributors, spironolactone (an oral medication) can help. Results take 4-6 months to appear.
When to see a dermatologist: If you notice your part widening, your ponytail getting thinner, or more hair on your brush than usual — especially if it started suddenly, which may point to a different cause that needs testing.
What Is Female Pattern Hair Loss?
Female pattern hair loss is the most common type of hair loss in women. Unlike male-pattern baldness (where the hairline recedes in an M-shape), women typically keep their front hairline but notice gradual thinning across the crown and top of the scalp. You might first notice your part looking wider, seeing more scalp when your hair is pulled back, or your ponytail feeling thinner.
Dermatologists classify female hair loss using the Ludwig scale (grades I-III) or the Sinclair scale (grades 1-5). Grade I is mild widening of the part; Grade III is significant thinning visible through the hair even when styled.
FPHL can start as early as the late teens, though it becomes more common after menopause. About 12% of women first notice thinning by age 29, rising to over 50% by age 79.
What Causes It?
Genetics and hormones: Like male pattern hair loss, FPHL involves sensitivity to androgens (male-type hormones that women also produce in smaller amounts). The hormone DHT causes hair follicles to gradually shrink, producing thinner, shorter hairs over time. You can inherit this sensitivity from either parent.
Hormonal changes: Many women notice hair thinning during or after menopause, when estrogen levels drop and the relative influence of androgens increases. Conditions that raise androgen levels — like polycystic ovary syndrome (PCOS) — can trigger earlier or more noticeable hair loss.
Other factors your doctor may check: Thyroid disorders, iron deficiency, vitamin D deficiency, and certain medications can cause or worsen hair thinning. These are important to rule out because they're treatable independently.
Getting Diagnosed
Your dermatologist will examine the pattern of thinning (diffuse thinning with preservation of the hairline is the hallmark). They may also:
Check your blood: A panel typically includes thyroid function (TSH), iron studies (ferritin), complete blood count, and sometimes DHEA-S and testosterone levels. Low ferritin (below 40 ng/mL) can contribute to hair loss even when you're not technically anemic.
Perform dermoscopy: A magnified scalp exam revealing hairs of varying diameter — the telltale sign of pattern hair loss.
Consider a scalp biopsy: Rarely needed, but helpful if the diagnosis is uncertain or if scarring hair loss needs to be ruled out.
Treatment Options
Minoxidil (Rogaine): The first-line treatment for FPHL. The 5% foam is typically recommended, applied once daily to the scalp. Studies show it produces moderate regrowth in about 40% of women and stabilizes hair loss in most others. Results take 4-6 months to become visible. You must continue using it — thinning resumes within months of stopping. Side effects include occasional scalp irritation and unwanted facial hair growth (which usually resolves by applying carefully to the scalp only).
Spironolactone: An oral medication (100-200mg daily) originally designed as a blood pressure drug that also blocks androgen effects. Widely used off-label for FPHL, especially in women with signs of excess androgens (acne, unwanted body hair). Takes 6-12 months to show improvement. Not safe during pregnancy — effective contraception is required. Side effects can include breast tenderness, irregular periods, and frequent urination.
Low-dose oral minoxidil: An emerging option (0.25-2.5mg daily by mouth) gaining popularity because many women find it easier than applying a topical solution daily. Early studies show comparable results to topical minoxidil. Side effects at low doses may include slight increases in body/facial hair and rare mild ankle swelling.
Platelet-rich plasma (PRP): Injections of concentrated growth factors from your own blood into the scalp. Studies show improvements in hair density, especially when combined with other treatments. Typically requires 3-4 sessions initially with maintenance every 6-12 months.
Hair transplant surgery: An option for women with stable, well-defined thinning areas and good donor hair density. Not all women are candidates — a thorough evaluation is important.
What Won't Work
Many supplements, shampoos, and devices marketed for hair growth have minimal or no evidence behind them. Biotin supplements are commonly promoted but only help if you have an actual biotin deficiency (which is rare). Expensive "hair growth" shampoos and serums typically don't penetrate the scalp deeply enough to affect follicle biology. Save your money for treatments with real clinical evidence.
Living With FPHL
While treatment can improve things, many women find it helpful to work with a stylist experienced in thinning hair. Volumizing cuts, hair fibers, and targeted styling can make a meaningful cosmetic difference while treatments take effect. Many women also find that connecting with others experiencing hair loss — through support groups or online communities — helps with the emotional side.
Frequently Asked Questions
Can birth control pills help with hair loss?
Some can. Birth control pills containing anti-androgenic progestins (like drospirenone in Yaz, or norgestimate in Ortho Tri-Cyclen) may help stabilize hair loss. However, pills containing androgenic progestins (like levonorgestrel) can actually worsen it. Ask your dermatologist or gynecologist which formulation is best for your situation.
Could my hair loss be from something other than pattern hair loss?
Yes — other common causes include telogen effluvium (temporary shedding after stress, illness, or hormonal shifts), thyroid disease, iron deficiency, and autoimmune conditions like alopecia areata. A dermatologist can distinguish between these based on the pattern and blood work. Sudden hair loss or patches of complete baldness suggest something other than FPHL.
Is PRP worth the cost?
PRP has growing evidence showing real improvements in hair density, though results vary by individual. It works best as an add-on to minoxidil or spironolactone rather than a standalone treatment. Costs typically run $500-$1,500 per session, and insurance doesn't cover it. Discuss with your dermatologist whether you're a good candidate.
Will my hair grow back completely?
Full restoration is unlikely — the goal is to slow further loss, thicken existing hairs, and regrow as much as possible. Early treatment produces better results because it's easier to rescue thinning follicles than revive fully dormant ones. Many women see meaningful improvement that makes a real cosmetic difference.
References
- Messenger AG, Sinclair R. Follicular miniaturization in female pattern hair loss. British Journal of Dermatology. 2006;155(5):926-930.
- Ramos PM, Miot HA. Female pattern hair loss: a clinical and pathophysiological review. Anais Brasileiros de Dermatologia. 2015;90(4):529-543.
- Sinclair R, et al. Treatment of female pattern hair loss with oral antiandrogens. British Journal of Dermatology. 2005;152(3):466-473.
- Olsen EA, et al. A multicenter randomized placebo-controlled double-blind clinical trial of a novel formulation of 5% minoxidil for androgenetic alopecia in women. Journal of the American Academy of Dermatology. 2007;57(5):767-774.
- Vano-Galvan S, et al. Oral minoxidil in female pattern hair loss. Journal of the American Academy of Dermatology. 2019;81(3):758-761.
- Gupta AK, et al. Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. Journal of Dermatological Treatment. 2017;28(1):55-58.
- Camacho-Martinez FM. Hair loss in women. Seminars in Cutaneous Medicine and Surgery. 2009;28(1):19-32.